All team members
Dr. Marco Stief
Partner
Attorney-at-Law
LL.M. University of Chicago
Head of Legal Department
Marco is a highly experienced lawyer, skilled in handling national and international patent infringement cases, border seizure proceedings and conflicts arising from technology-related contracts. He advises companies in the areas of technical IP rights, technology transfers and also on a wide variety of contractual matters. He acts in an advisory capacity on questions relating to design rights, competition law, employee inventions and trade secrets.
Marco has headed Maiwald’s legal department since 2017. He lectures in intellectual property rights at the University of Dresden and is associate lecturer in patent and international contract law at the University of Marburg.
"Marco Stief is an expert in intellectual property law and is commended by peers for his strategic patent litigation in the life sciences sector."
– Who's who Legal IP, 2024
"Marco Stief earns extensive endorsements as a leading figure in the market with broad knowledge of the life sciences industry and regulatory environment."
– Who's who Legal IP, 2024
“Very well versed in the crossroads of legal and regulatory issues in the life sciences arena.”
– IAM Strategy 300, 2024
“Marco Stief is very experienced litigator and negotiator. He always sees the big picture and keeps the client’s prerogatives in mind.”
– IAM Strategy 300, 2024
"Marco Stief is an expert in intellectual property law and is commended by peers for his strategic patent litigation in the life sciences sector."
– Who is Who Legal, 2024
"Marco Stief earns extensive endorsements as a leading figure in the market with 'broad knowledge of the life sciences industry and regulatory environment'."
– Who is Who Legal, 2024
"With robust enforcement experience and deep knowledge of the laws governing tech transfer agreements and patent licensing, Marco Stief is an excellent adviser for patent legal issues. When not advising clients, Stief lectures aspiring IP professionals at two universities."
– IAM Patent 1000, 2023
"Marco Stief is highlighted by market sources as 'a trusted adviser and excellent litigator' who 'knows all the tricks' and has 'great experience in particular in pharma-related matters'"
– Who´s Who Legal, 2023
"With Marco Stief you can tell that he knows the industry through and through. In addition to excellent legal knowledge, he has a quick technical understanding of our very different products. What is decisive for us, however, is that he always keeps an eye on the long-term consequences and knows the market and related areas of law very well. This enables him to develop creative solutions and to discuss possible solutions and strategies directly at management level."
– Legal 500 EMEA, 2023
"Marco Stief stands out among peers for his in-depth patent knowledge and clear focus on pharmaceutical-related IP matters."
– Who's Who Legal, 2022
“Excellent litigator' Marco Stief is described as 'experienced and knowledgeable' by peers for his work in the patent arena."
– Who's Who Legal, 2022
"Marco Stief is one of the leading individuals in Germany for patent strategy, particularly in the pharmaceutical field. Marco maintains one of the best Supplementary Protection Certificate practices in the country and is considered a thought leader in this space."
– IAM 300, 2022
“very experienced in pharma litigation, extraordinary knowledge of SPCs”
– JUVE Patent, 2021
"Heading up the legal department is seasoned attorney at law Marco Stief, who is equally proficient in litigation and licensing scenarios. Recent credits include acting in preliminary injunction proceedings on behalf of Fresenius against Eli Lilly."
– IAM Patent 1000, 2021
"Stief, der das Rechtsanwaltsteam leitet, gilt in der Branche als ausgewiesener Experte für Lizenzen u. Fragen rund um Verlängerungspatente für Arzneien (SPCs)."
– JUVE, 2021
"Marco Stief, who 'brings great technical understanding and a very outcome-oriented and practical approach to any project, is always very responsive and has a brilliant strategic mind'. 'He is very convincing in court and always thinks one step ahead.'"
– IAM Patent 1000, 2020
“Marco Stief is highly regarded for his sound technical knowledge and ability to devise sophisticated strategies that to resolve infringement. He stands his ground to the end, but also recognises when an alternative approach is necessary.”
– IAM Strategy 300, 2023
“highly competent”, “very focussed”, “long-standing experience in pharma litigation”, “sophisticated strategist”
– JUVE Patent Germany rankings, 2023
"Marco Stief: Very good litigator and licensing expert." "Derk Vos and Marco Stief are both extremely pleasant colleagues who know the market like the back of their hand and are very well connected."
– The Legal 500 Deutschland 2024
"I have worked with one of their attorneys at law, who is very pleasant. Stief is quite smart and good in his cooperation."
– CLIENT | CHAMBERS EUROPE 2024
Captaining the team of attorneys-at-law and taking them from strength to strength, Marco Stief is “highly knowledgeable in the life sciences field and is an outstanding expert to have onside for pharmaceutical and SPC litigation”.
– IAM Patent 1000, 2024
“indisputably high level of competence, we’re happy”, Client “thorough and dedicated”, “expert in patent litigation for biotech and pharma”, Competitors
– JUVE Patent, 2024
- Patent Litigation
- Drafting and negotiating IP and technology transfer agreements
- Advice on German employee invention law
- Pharmaceutical law
- Listed in the WirtschaftsWoche "Die renommiertesten Patentrechtsanwälte" 2020, 2021, 2022, 2024
- Listed as “Thought Leader IP” and “Recommended” in Who's who Legal IP, 2024
- Listed in IAM Strategy 300 as one of the world's leading IP strategists 2021, 2022, 2023, 2024
- Listed as "Excellent" in the Patent Litigation category and as "Highly recommended" in the Healthcare & Pharmaceuticals category in the Leaders League Rankings Germany 2024
- Recommended in Handelsblatt | Best Lawyers "Germany's Best Lawyers" 2019, 2020, 2021, 2022, 2023, 2024
- Listed in Handelsblatt as lawyer of the year in the category healthcare law 2021, 2024
- Recommended in MIP IP Stars 2017, 2021, 2022, 2023, 2024
- Recommended in Legal 500 EMEA 2019, 2020, 2021, 2022, 2023, 2024
- Recommended in Legal 500 Deutschland 2017, 2019, 2020, 2021, 2022, 2023, 2024
- Listed in IAM Strategy 300 Global Leaders 2021, 2022, 2023, 2024, 2025
- World IP Review: Patent Leader Germany 2022, 2023
- For many years listed in IAM Patent 1000 „The World’s Leading Patent Professionals“
- Named in Who’s Who Legal 2019 and 2020 as one of the six most highly regarded German patent litigators, recognized by Who’s Who Legal as Thought Leader (Germany) in Patent Law (2021), Global Leader IP-Patents (2021), Life Sciences Patent Litigation (2022), National Leader Germany-Patents (2022, 2023), Thought Leader Germany-Patents (2022), Global Leader IP-Patents (2022), Listed as One of the world’s leading practitioners in the Who's Who Legal: IP 2023 report, recommended in the "Germany" and "Life Science" ranking (2024)
- Listed as Leading Lawyer in Patent Litigation in the JUVE Patent Rankings Germany 2022, 2023, 2024
- Recommended in the Leaders League Rankings Germany 2022 and 2023 in the category Patent Litigation
- Scholar of the German Academic Exchange Service (DAAD)
- Listed in JUVE Patent as "Advisor in patent litigation" 2020/2021
- Listed in Handelsblatt 2021 as best lawyer for Healthcare in Bavaria
- Listed as best lawyer in Handelsblatt 2021 in the categories Biotechnology Law, Healthcare Law and Pharmaceutical Law
- Named in JUVE Top 8 German patent litigators under 50 2019/2020/2021
- Listed in WirtschaftsWoche "Die besten Anwälte für Patentrecht und Urheberrecht" 2019
- Recommended in Expert Guides - Life Sciences for IP and Regulatory 2019, 2021
- Named in JUVE Top 12 German patent litigators under 50 2018/2019/2020
- Named in Chambers Europe 2018
- Winner of the “Client Choice Award 2015/2016 for Patent Law”
- Listed in „WiWo Top-Kanzleien“ als Top Attorney for Patentlaw in 2018 & 2021
- Recommended in WirtschaftsWoche 2015
- For many years listed in IAM Strategy 300 „World’s Leading IP Strategists“
- For many years “frequently recommended lawyer” in the JUVE Handbook of Commercial Law Firms
- Scholar of the German Bundestag
- Fulbright Scholar
- Rotary International Foundation (Ambassadorial Scholarship Scholar)
- Interview IAM Strategy 300 Global Leaders, 2024
- Klinische Studien als neuheitsschädliche Vorbenutzung im Sinne von § 3 PatG, PharmR 8/2024 (German only)
- Die Marktexklusivität als absolutes Recht (Teil II), GRUR 16/2024
-
Wündisch/Zirkel, F&E-Verträge, Handbuch für Wissenschaft und Praxis, 2024 (German only)
Chapter on the Unified Patent Court and Unitary Patent and on the special features of research and development in the pharmaceutical and life sciences sector - Impact of the Unitary Patent and the Unified Patent Court on Patent Owners, Licensees and Technology Firms and Recommendations, Zhichanli, 2024 (Chinese only)
- Die Marktexklusivität als absolutes Recht (Teil I), GRUR 11/2024
- Wettbewerbsrecht im Kontext von Technologietransfer- und Lizenzverträgen, PharmR 4/2024
- Not without my consent – Zu den Grenzen des SPC squatting, GRUR 6/2024
- Unitary Patent and Unified Patent Court – the new europe-wide patent and court system, Zhichanli, 2024 (Chinese only)
- § 945 ZPO – Ausweitung der Haftung der Originatoren bei später widerrufenem Patent?, GRUR 4/2024 (Stief/Meyer)
- Wettbewerbsrecht im Kontext von F&E- und Linzenzverträgen, PharmR 3/2024
- Rechtshandbuch Chemie-, Pharma- und Life-Science-Patente, C.H. Beck – 2023
- (No) injunctive relief before the actual grant of a patent, GRUR 23/2023
- Does current legislation provide for adequate compensation in cases of unjustified preliminary injunctions? Originator–generic conflicts in the context of patent infringement proceedings, Journal of Intellectual Property Law & Practice, 12/2023 (Stief/Geller)
- The springboard doctrine in the context of patent law – part one, Managing IP 2023
- The springboard doctrine in the context of patent law – part two, Managing IP 2023
- European Unitary Patent Package: Introduction to the New System including Strategic Considerations, (September 2023) 133 Intellectual Property Forum 40
- European Commission proposes transferable data exclusivity vouchers to tackle the antimicrobial resistance crisis, Managing IP 2023
- 単一特許と統一特許裁判所（2）特許権者，ライセンシー，テクノロジー企業が受ける影響と進言, AIPPI, 2023
- 単一特許と統一特許裁判所（1）新たな欧州全域の特許と裁判所制度, AIPPI, 2023
- Ersatzansprüche bei ungerechtfertigten einstweiligen Verfügungen im Pharmabereich – Ansprüche des Antragsgegners und geschädigter Dritter, GRUR 13/2023
- Quo vadis Arzneimittelrecht – ein Überblick zur Überarbeitung der EU-Arzneimittelvorschriften, PharmR 6/2023
- Der texanische “Two-Step”- Umstrittene juristische Strategie zur Begrenzung der Unternehmenshaftung, Arzneimittel & Recht 2/23
- EuGH: Plattformbetreiber haften für Markenrechtsverletzungen durch Drittanbieter – der Fall Louboutin/Amazon, BetriebsBerater 12/2023
- Der patentrechtliche Verhältnismäßigkeitsgrundsatz im Bereich Arzneimittel und Medizinprodukte, Teil 2, PharmR 3/2023
- Pharmaceutical, Biological and Chemical Patents, C.H.BECK – 2023
- Louboutin v Amazon: direct liability of online platforms for third-party trademark infringement, MIP 2023
- Die Einführung eines neuen Patentsystems in Europa, Betriebs-Berater 2023, Heft 09
- No-challenge and pay-for-delay agreements in patent licence and settlement agreements under European competition law, Journal of Intellectual Property Law & Practice, Vol. 18/2, 02/2023, S.135–145
- Der patentrechtliche Verhältnismäßigkeitsgrundsatz im Bereich Arzneimittel und Medizinprodukte, Teil 1, PharmR 2/2023
- Europe’s new Unitary Patent System will affect IP Agreements, Law360 2023
- Die Reform der Gruppenfreistellungsverordnungen – FuE- und Spezialisierungs-GVO 2023, Wirtschaft und Wettbewerb 01/2023
- IP as a means of securing a loan under German law, Managing IP 2023
- Interview IAM Strategy 300 Global Leaders, 2023
- Einheitspatent und einheitliches Patentgericht – Konsequenzen für Schutzrechte und Technologieverträge, PharmR 12/2022
- Article No challenge clauses Pay-for-delay agreements, A.I.P.P.I. Japanese Journal Vo.67 No. 3 p.31 2022 (Japanese only)
- Proportionality defence v compulsory licence: the decision of the Düsseldorf court, Managing IP 2022
- IP Due Diligence und Pharma, |transkript 4-2022 im November – Spezial: “Patente / M&A / Lizenzierung”
- Preisanpassungsklauseln bei Verträgen zwischen Unternehmen, Betriebs-Berater 43/2022
- Einheitspatent und einheitliches Patentgericht – Vorstellung des neuen europaweiten Patent- und Gerichtssystems, PharmaR Heft 10/2022
- Ergänzende Schutzzertifikate – Überblick und Ausblick zur EU-Initiative, Arzneimittel & Recht, 2022
- Originator vs Generika – Pharmapatente im Spannungsfeld des einstweiligen Verfügungsverfahrens, PharmR Heft 6/2022, Heft 8/2022
- Regulatorische und haftungsrechtliche Herausforderungen für KI-Medizinprodukte, in Roman Grinblat/ Sibylle Scholtz/ Sophy Stock (Hrsg.) Festschrift für Ulrich M. Gassner, Medizinprodukterecht im Wandel (S. 467 ff.), Nomos, 2022
- Do the experimental use and bolar exemptions also apply in contributory patent infringement cases? Journal of Intellectual Property Law and Practice, 2022
- EU-Initiative zu Zwangslizenzen – Chance oder Wettbewerbsnachteil? Arzneimittel & Recht, 2022
- Haftungsbegrenzungen und Freistellungsvereinbarungen insbesondere in Technologie- und Unternehmenskaufverträgen (M&A), Lizenz- und F&E-Verträgen, 2022
- Vertragliche IP Garantien in Pharmaverträgen, insbesondere M&A, Lizenz und F&E Verträge, 2022
- Vertragshandbuch Pharma und Life Sciences, C.H.BECK, 2., erw. Auflage – 2021 (gemeinsam hrsg. mit Boris Bromm)
- Admissibility of non-challenge clauses and pay-for-delay agreements in settlements and license, 2021
- What is Horizon Europe about? (2021)
- Patent(e) Sicherheit in unsicheren Zeiten, 2021
- The launch of Horizon Europe: The EU initiative for research and innovation, 2021
- Connected Cars, SEP and Frand-Cjeu Referral With a Focus on Multi-Tier Supply Chains, 2021
- CJEU SANTEN: No More SPC protection for new indications and new galenic formulations? (2021)
- Das Ende von SPCs für neue Indikationen? (2020)
- Lieferengpässe in der Arzneimittelindustrie – Ursache, Gründe und Lösungsansätze am Beispiel des Corona Virus (Teil 2), 2020
- Lieferengpässe in der Arzneimittelindustrie – Ursache, Gründe und Lösungsansätze am Beispiel des Corona Virus (Teil 1), 2020
- Handbuch des Patentrechts, 2. Auflage, 2020
- Rechtliche Probleme des ergänzenden Schutzzertifikats für Arzneimittel, 2020
- Pregabalin and Fulvestrant – a comparison of German and English liability regimes for Swiss-type claims in light of current case law
- New Liability for Second Medical Use, 2019
-
Pharmaceutical, Biological and Chemical Patents, C.H.BECK, 2019 (gemeinsam hrsg. mit Maximilian Haedicke und Dirk Bühler)
-
Vertragshandbuch Pharma und Life Sciences, C.H.BECK, 2. Auflage, 2019 (gemeinsam hrsg. mit Boris Bromm)
- Process patents and the partial outsourcing of individual procedural steps into patent-free foreign countries – opportunity or risk? (2018)
- Designrechtler, 2017
- Recent developments in German jurisprudence following ECJ “Huawei Technologies / ZTE“, 2017
-
Supplementary Protection Certificates (SPC), C.H.BECK, Stief/Bühler (published together), 2016
- CJEU requirements in FRAND cases, 2016
- BGH “Filmscanner” judgment reviewed, 2016
- Safe harbors in Europe: an update on the research and Bolar exemptions to patent infringement, 2015
- Revised TTBER and Guidelines, 2015
- Patent Law – A Handbook on European and German Patent Law, 2014
- Questions submitted on scope of Bolar provision, 2014
-
Handbuch des Patentrechts, Haedicke/Timmann (Hrsg.), C.H.BECK, 2012 (together with Johannes W. Bukow et al.)
- Neurim and SPCs: Justice for indication inventions, 2012
-
Praktische Erfahrung mit der Grenzbeschlagnahme nach VO (EG) Nr. 1383/2003, in: Festschrift für Ulf Doepner, Reese/Hufnagel/Lensing-Kramer (Hrsg.), C.H.BECK, 2008 (gemeinsam mit Peter Chrocziel)
- Bar Association
- GRUR
- DAV
- DAJV
- VPP
- LES
- Founding Member IPDR
- German
- English
